Immuron Posts $2.2M Q1 FY27 Sales as Travelan Relaunch Lifts Australia 14% [VIDEO]

Immuron Travelan sales growth powered a 9% lift in Q1 FY27 sales to $2.2 million, with Australia up 14% and Canada surging 286% even as the US slipped 19%.

By Josua Ferreira -

Key Takeaways

  • Immuron lifted Q1 FY27 global sales 9% on pcp to $2.2 million, up 5% on the prior quarter.
  • Travelan grew 26.4% in Australian pharmacy against category growth of 5.3%, and outsold Imodium in total pharmacy sales over the last 13 weeks to 26 September 2026.
  • Australia delivered $1.8 million, up 14% on pcp, after the Travelan brand re-launch with new packaging.
  • Canada jumped 286% to $0.1 million, but the small base means the percentage overstates the dollar impact.
  • US sales fell 19% to $0.3 million; management blames Prime Day timing and logistics delays, and points to October and November sales events for the next quarter.
This is a special feature video produced for our partner.

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher